论文部分内容阅读
目的观察鳖甲煎丸联合恩替卡韦治疗乙型肝炎肝硬化患者的临床疗效。方法 86例乙型肝炎肝硬化患者随机分为治疗组和对照组各43例。治疗组给予鳖甲煎丸联合恩替卡韦治疗;对照组仅给予恩替卡韦治疗。观察治疗前、治疗12周、治疗24周、治疗48周时,观察两组患TBIL、ALT、HBV-DNA、肝纤维化指标的变化。结果治疗48周时两组患者在ALT的复常率、HBV-DNA比较无明显的差异(P>0.05),但两组患者在肝纤维化指标的改善上和总胆红素的下降上比较有明显的差异(P<0.05),两组患者在治疗的过程中未见明显的不良反应。结论鳖甲煎丸联合恩替卡韦治疗乙型肝炎肝硬化,可明显改善肝脏功能和促进黄疸下降。
Objective To observe the clinical efficacy of Biejiaofu Pill combined with entecavir in the treatment of hepatitis B cirrhosis patients. Methods 86 cases of hepatitis B cirrhosis were randomly divided into treatment group and control group, 43 cases each. The treatment group was given Biejiaofu Pill combined with entecavir treatment; the control group only given entecavir treatment. Before treatment, 12 weeks of treatment, 24 weeks of treatment, 48 weeks of treatment, the changes of TBIL, ALT, HBV-DNA and liver fibrosis were observed in both groups. Results At 48 weeks, there was no significant difference in ALT normalization rate and HBV-DNA between the two groups (P> 0.05). However, the improvement of liver fibrosis index and total bilirubin in both groups were compared There was a significant difference (P <0.05). There was no obvious adverse reaction in both groups during the course of treatment. Conclusion Biejiaotai pill combined with entecavir treatment of hepatitis B cirrhosis can significantly improve liver function and promote the decline of jaundice.